The first drug designed entirely using artificial intelligence is entering clinical human trials in what has been described as a major milestone in medicine.
The new compound, which has been designed for treating obsessive-compulsive disorder, was discovered using Oxford-based biotech company Exscientia’s AI system.
Continue reading Drug designed by AI to enter human trials for first time